3BBLACKBIO
3B BlackBio Dx Ltd
Each stock's 10,000-path forecast, rendered as light.
3B BlackBio Dx Ltd (3BBLACKBIO) Stock Analysis & Case Study
Is 3BBLACKBIO a good buy? The data-driven verdict.
3B BlackBio Dx Ltd (3BBLACKBIO) trades at ₹1,208,on the numbers it worth a closer look, a Downstox Snapshot Score of 63/100.
On the numbers, 3B BlackBio Dx Ltd (3BBLACKBIO) worth a closer look, a Downstox Snapshot Score of 63/100, weighing fairly valued at 17.7× earnings, ROE of 19.8%, a 49% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
3BBLACKBIO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How 3BBLACKBIO ranks against the 2,373 companies in our screener
- 3BBLACKBIO's market cap of 1,037 Cr ranks in the 40th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's book value of ₹378 ranks in the 85th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's promoter holding of 41.0% ranks in the 17th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's 3-year profit (PAT) growth of 31.0% ranks in the 70th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's 3-year revenue growth of 32.0% ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's debt-to-equity ratio of 0.01x is lower than 98% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is 3BBLACKBIO overvalued? 3BBLACKBIO P/E vs peers
3BBLACKBIO trades at 17.7× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
3BBLACKBIO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of 3BBLACKBIO history (48%/yr drift, 54%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| 3BBLACKBIO 2027 | ₹598 | ₹1,194 | ₹2,383 | -1% |
| 3BBLACKBIO 2028 | ₹450 | ₹1,179 | ₹3,089 | -2% |
| 3BBLACKBIO 2029 | ₹344 | ₹1,165 | ₹3,946 | -4% |
| 3BBLACKBIO 2030 | ₹278 | ₹1,150 | ₹4,757 | -5% |
| 3BBLACKBIO 2031 | ₹234 | ₹1,136 | ₹5,513 | -6% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability 3BBLACKBIO goes up, or doubles?
The bull case for 3BBLACKBIO
- 3BBLACKBIO's P/E of 17.7x is lower than 67% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's return on equity of 19.8% ranks in the 83rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- 3BBLACKBIO's return on capital employed of 25.5% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,946.
The bear case & risks
- High historical volatility (54%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹344.
3BBLACKBIO volatility & expected range, how bumpy is the ride?
Over the last 9.8 years 3BBLACKBIO compounded at 48%/year with annualized volatility of 54%. That volatility implies a 1-year 80% range of ₹598-₹2,383, the honest backbone behind any single price target.
3BBLACKBIO price forecast, the full 60-month probability fan
3BBLACKBIO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds 3BBLACKBIO hits common targets within the simulated horizon?
Full multi-horizon detail on the 3BBLACKBIO price target & forecast page.
3BBLACKBIO Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. 3BBLACKBIO scores 6/8, mixed financial health.
3BBLACKBIO MTF margin & leverage across 4 brokers
Margin Trading Facility lets you buy 3BBLACKBIO with part of the capital. Lower margin % = higher leverage. Rates compared across 4 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Zerodha | 50.00% | 2.0× |
| Groww | 38.97% | 2.6× |
| Pocketful | 50.00% | 2.0× |
| Share IndiaCHEAPEST | 38.92% | 2.6× |
Compare every broker on the 3BBLACKBIO MTF page.
About 3B BlackBio Dx Ltd: sector, index & market-cap context
3B BlackBio Dx Ltd (3BBLACKBIO) is a small-cap NSE-listed company, with a market capitalisation of ₹1,037 Cr. See more stocks on our screener.
How the 3BBLACKBIO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of 3B BlackBio Dx Ltd's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
3BBLACKBIO analysis, FAQs
Is 3B BlackBio Dx Ltd (3BBLACKBIO) a good buy?
On the numbers, 3B BlackBio Dx Ltd (3BBLACKBIO) worth a closer look, a Downstox Snapshot Score of 63/100, weighing fairly valued at 17.7× earnings, ROE of 19.8%, a 49% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is 3BBLACKBIO overvalued or undervalued?
3BBLACKBIO trades at 17.7× earnings, fairly valued versus the ~22× long-run Nifty average.
What is the 3BBLACKBIO share price target for 2031?
3BBLACKBIO's probability-weighted 2031 median target is ₹1,136, with an 80% range of ₹234-₹5,513 (10,000-path Monte-Carlo).
What is the probability 3BBLACKBIO doubles in 5 years?
The modelled probability of 3BBLACKBIO reaching ₹2,418 (2×) within 5 years is 27%.
What is the bull case for 3BBLACKBIO?
3BBLACKBIO's P/E of 17.7x is lower than 67% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. 3BBLACKBIO's return on equity of 19.8% ranks in the 83rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. 3BBLACKBIO's return on capital employed of 25.5% ranks in the 88th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in 3BBLACKBIO?
High historical volatility (54%/yr) means a wide, bumpy range of outcomes, size positions accordingly.